The World Health OrganizationÂ has said the only approved vaccine againstÂ malaria should be widely given to African children, marking a major step forward in the fight against a disease that kills hundreds ofÂ thousands of people annually. On Wedensday, the WHO recommended thatÂ theÂ Mosquirix (RTS,S) vaccineÂ developed by British drugmaker GlaxoSmithKline be rolled-out across African countries. Since 2019, 2.3 million doses of Mosquirix have beenÂ administered to infants in Ghana, Kenya and Malawi in aÂ large-scale pilot programme coordinated by the WHO. The majorityÂ of those whom the disease kills are under age five, and the pilotÂ programme followed a decade of clinical trials in sevenÂ African countries. A child dies from #malaria every two minutes.One death is one too many.ğŸš¨ Today, WHO recommends RTS,S, a groundbreaking malaria vaccine, to reduce child illness & deaths in areas with moderate and high malaria transmission https://t.co/xSk58nTIV1#VaccinesWork pic.twitter.com/mSECLtRhQs According toÂ WHO director-general Tedros Ghebreyesus,Â "This is a vaccine developed in Africa by African scientistsÂ and we're very proud." "Using this vaccine in addition to existing tools to preventÂ malaria could save tens of thousands of young lives each year," he added, referring to anti-malaria measures like bed nets andÂ spraying to kill mosquitoes that transmit the disease. One of the ingredients in the Mosquirix vaccine is sourcedÂ from a rare evergreen native to Chile called a Quillay tree. However, the long-term supply of these trees is reportedly in question. Malaria is far more deadly than Covid-19 in Africa. ItÂ killed 386,000 Africans in 2019, according to a WHO estimate,Â compared with 212,000 confirmed COVID-19 deaths in the past 18Â months. The WHO says 94% of malaria cases and deaths occur inÂ Africa, a continent of 1.3 billion people. WHO eyes malaria eradication in 25 countries by 2025  	'Landmark' step in malaria vaccines as first trial meets WHO target The vaccine's effectiveness at preventing severe cases ofÂ malaria in children is only around 30%, but it is the onlyÂ approved vaccine. The European Union's drugs regulator approvedÂ Mosquirix in 2015, saying its benefits outweighed the risks. Another vaccine against malaria called R21/Matrix-M that wasÂ developed by scientists at Britain's University of Oxford has showedÂ up to 77% efficacy in a year-long study involving 450 childrenÂ in Burkina Faso. It is still, however, in theÂ trial stages. Daily newsletterReceive essential international news every morning Keep up to date with international news by downloading the RFI app